AI in COA Translation

The conversation around AI in Clinical Outcome Assessment (COA) translation and linguistic validation processes has evolved rapidly. With the recent publication from the ISOQOL AI Working Group, the industry now has something it has long been missing: clear, experience-based recommendations on where AI adds value (and where it doesn’t). For Lionbridge’s COA translation team, this shift is less like a disruption and more like a validation. Through our team’s previous research, posters, and client work, we’ve already seen many of these patterns emerge in practice.

An Industry Trend Toward Targeted AI Adoption in COA Translation

The study highlights a critical turning point. AI is no longer being assessed as a theoretical capability. It’s being evaluated step by step across linguistic validation and Electronic Clinical Outcome Assessment (eCOA) processes. Some key takeaways include:

• Strong alignment on efficiency gains: 86% of stakeholders expect AI to reduce timelines

• High suitability for structured, technical tasks: eCOA migration and proofreading are prime candidates for AI support

• Growing acceptance of hybrid translation models: Combining AI with human translators (e.g., one AI-assisted forward translation) is increasingly viewed as a viable approach

Notably, the study reinforces an equally important message: AI is not a replacement for human expertise in linguistic validation.

Where AI Stops in COA Translation

Despite the fast momentum of AI acceptance, the Life Sciences industry draws clear boundaries. Research shows consistent hesitation around using AI in high-context, patient-centric steps:

• Cognitive debriefing interviews remain firmly human-led

• Reconciliation and clinical review require expert judgment

• Cultural nuance and patient understanding still depend on human empathy

Additionally, intellectual property and data security concerns remain significant. More than half of stakeholders express concern about AI-related risks. This reinforces the view that the value of AI delivers the most value through augmentation rather than substitution. 

How Lionbridge Aurora AI Clinical Outcomes™ Applies AI in COA Translation

As eCOA providers, Lionbridge has operationalized this hybrid approach through our Aurora AI Clinical Outcomes solution. Rather than applying AI broadly, Aurora AI Clinical Outcomes embeds AI where it delivers value while still preserving human oversight at every critical step.

1. AI to drive efficiency and consistency. Aurora AI Clinical Outcomes leverages AI to support these areas where the ISOQOL study also found strong alignment with AI capabilities:

   • Concept definition and content structuring

   • Comparative review and consistency checks

   • eCOA migration and QA processes

2. Human expertise where it’s needed. Aurora AI Clinical Outcomes maintains full human control over:

   • Final translation decisions

   • Reconciliation and linguistic validation

   • Cognitive debriefing and patient-facing activities

   This approach ensures that conceptual equivalence, cultural appropriateness, and regulatory compliance are never compromised.

3. Built for optimal security and IP protection. In line with industry concerns, Aurora AI Clinical Outcomes is designed with:

   • Secure environments and controlled data handling

   • No uncontrolled data exposure to public AI models

   • Full transparency on where and how AI is used

4. A shift in differentiation. One of the most important implications of this study is its reframing of competitive advantage in the Life Sciences industry. The question is no longer about using AI, but rather how to use AI to enhance quality and protect patient outcomes. This is where Lionbridge sees the greatest opportunity—and responsibility.